Beam Therapeutics price target raised to $45 from $43 at BofA

BofA analyst Alec Stranahan raised the firm’s price target on Beam Therapeutics (BEAM) to $45 from $43 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items “have fallen into place,” including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.